Breast cancer
We form a long-term antitumor defense, reducing the risks of relapses and metastasis.
About the disease
In breast cancer, it is essential not only to fight the primary tumor but also to prevent relapses.
Immunotherapy forms long-term antitumor immunity, supplementing surgical treatment.
Relapse prevention
Immune surveillance destroys residual cells.
Surgical synergy
Enhances the result of the operation.
No intoxication
Gentle impact on the body.
Extracorporeal immunotherapy
We move the immune 'training' process outside the body (ex vivo) — to an environment where we can create the conditions for training immunocompetent cells without creating any risk to your body.
Procedure
We draw your venous blood (up to 90 ml).
Activation (18 hours)
In the laboratory, using our proprietary technology (patents in Russia, the US, and the EU), we incubate the cells with immunomodulatory drugs and xenogeneic antigens. The cells receive a precise target.
Strike
We return the trained cells via subcutaneous injections. A powerful, multi-component immune response is developed.
Consolidation
The maintenance course forms long-term immunological memory, protecting against relapses for years.
Other directions
Melanoma
Activation of your own cells to destroy metastases. Proven efficacy even at advanced stages.
Kidney cancer
Specific immune response against renal cell carcinoma without severe toxic burden.
Ovarian cancer
Adoptive therapy opening new treatment possibilities even when chemotherapy standards are exhausted.
Discuss your situation
Leave your contact details. Our medical coordinator will contact you shortly to answer any questions.